ABSTRACT
Since the US Food and Drug Administration (FDA) approved drug-eluting stents (DES) for the treatment of coronary artery disease in April 2003, the use of these devices has increased exponentially. By October of 2003, more than 250 000 sirolimus-eluting stents had been implanted in the USA alone.1
